Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients

Respiratory Research

Volumn 11, Issue , 2010, Pages

  Green, Deanna M ^a   McDougal, Kathryn E ^b   Blackman, Scott M ^a   Sosnay, Patrick R ^a   Henderson, Lindsay B ^a   Naughton, Kathleen M ^a   Collaco, J Michael ^a   Cutting, Garry R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; ASPERGILLUS; DISEASE SEVERITY; FEMALE; GENE MUTATION; HUMAN; INFECTION RISK; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MICROORGANISM DETECTION; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PSEUDOMONAS AERUGINOSA; CHILD; COMPARATIVE STUDY; CYSTIC FIBROSIS; FOLLOW UP; GENETICS; INFANT; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MUTATION; PHYSIOLOGY; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTION; TWINS;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; RESPIRATORY TRACT INFECTIONS; YOUNG ADULT;

EID: 77957576131     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-140     Document Type: Article

References (29)

1. Halliburton CS, Mannino DM, Olney RS. Cystic fibrosis deaths in the United States from 1979 through 1991. An analysis using multiple-cause mortality data. Arch Pediatr Adolesc Med 1996, 150:1181-1185.
2. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002, 34:91-100. 10.1002/ppul.10127, 12112774.
3. Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, Green CG, Collins J, Farrell PM. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001, 32:277-287. 10.1002/ppul.2009.abs, 11568988.
4. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001, 138:699-704. 10.1067/mpd.2001.112897, 11343046.
5. Courtney JM, Dunbar KE, McDowell A, Moore JE, Warke TJ, Stevenson M, Elborn JS. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 2004, 3:93-98. 10.1016/j.jcf.2004.01.005, 15463892.
6. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:814-821. 10.1164/rccm.200802-327OC, 18669817.
7. De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros 2007, 6:75-78. 10.1016/j.jcf.2006.05.011, 16793350.
8. Kanthan SK, Bush A, Kemp M, Buchdahl R. Factors effecting impact of Aspergillus fumigatus sensitization in cystic fibrosis. Pediatr Pulmonol 2007, 42:785-793. 10.1002/ppul.20656, 17659599.
9. Kubesch P, Dörk T, Wulbrand U, Kälin N, Neumann T, Wulf B, Geerlings H, Weibbrodt H, von der Hardt H, Tümmler B. Genetic determinants of airways' colonization with pseudomonas aeruginosa in cystic fibrosis. Lancet 1993, 341:189-193. 10.1016/0140-6736(93)90062-L, 7678316.
10. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003, 361:1671-1676. 10.1016/S0140-6736(03)13368-5, 12767731.
11. Koch C, Cuppens H, Rainisio M, Madessani U, Harms H, Hodson M, Mastella G, Navarro J, Strandvik B, McKenzie S. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 2001, 31:1-12. 10.1002/1099-0496(200101)31:1<1::AID-PPUL1000>3.0.CO;2-T, 11180668.
12. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009, 106:18825-18830. 10.1073/pnas.0904709106, 2773991, 19846789.
13. Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran S, Rogan MP, Davis GJ, Hanfland RA, Wohlford-Lenane C, Dohrn CL, Bartlett JA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010, 2:29ra31.
14. Vanscoy LL, Blackman SM, Collaco JM, Bowers A, Lai T, Naughton K, Algire M, McWilliams R, Beck S, Hoover-Fong J, et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 2007, 175:1036-1043. 10.1164/rccm.200608-1164OC, 1899267, 17332481.
15. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, LeGrys VA, Massie J, Parad RB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008, 153:S4-S14. 10.1016/j.jpeds.2008.05.005, 2810958, 18639722.
16. Blackman SM, Hsu S, Vanscoy LL, Collaco JM, Ritter SE, Naughton K, Cutting GR. Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis. J Clin Endocrinol Metab 2009, 94:1302-1309. 10.1210/jc.2008-2186, 2682466, 19126627.
17. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000, 16:749-767. 10.1034/j.1399-3003.2000.16d30.x, 11106223.
18. Taylor-Cousar JL, Zariwala MA, Burch LH, Pace RG, Drumm ML, Calloway H, Fan H, Weston BW, Wright FA, Knowles MR. Histo-blood group gene polymorphisms as potential genetic modifiers of infection and cystic fibrosis lung disease severity. PLoS ONE 2009, 4:e4270. 10.1371/journal.pone.0004270, 2627933, 19169360.
19. Zielenski J, Tsui LC. Cystic fibrosis: Genotypic and phenotypic variations. Annu Rev Genet 1995, 29:777-807. 10.1146/annurev.ge.29.120195.004021, 8825494.
20. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993, 73:1251-1254. 10.1016/0092-8674(93)90353-R, 7686820.
21. Ahmed N, Corey M, Forstner G, Zielenski J, Tsui LC, Ellis L, Tullis E, Durie P. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut 2003, 52:1159-1164. 10.1136/gut.52.8.1159, 1773762, 12865275.
22. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet 2003, 67:471-485. 10.1046/j.1469-1809.2003.00028.x, 12940920.
23. Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, Ramsey B. Disease-specific Reference Equations for Lung Function in Patients with Cystic Fibrosis. Am J Respir Crit Care Med 2005, 172:885-891. 10.1164/rccm.200410-1335OC, 15976373.
24. Welsh MJ, Ramsey BW, Accurso FJ, Cutting GR. Cystic Fibrosis. The Metabolic and Molecular Bases of Inherited Disease 2001, III:5121-5188. New York: McGraw-Hill, Inc, Scriver CR, Beaudet AL, Valle D, Sly WS, Eighth.
25. Schroeder TH, Lee MM, Yacono PW, Cannon CL, Gerceker AA, Golan DE, Pier GB. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc Natl Acad Sci USA 2002, 99:6907-6912. 10.1073/pnas.092160899, 124502, 11997458.
26. Bajmoczi M, Gadjeva M, Alper SL, Pier GB, Golan DE. Cystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa. Am J Physiol Cell Physiol 2009, 297:C263-C277. 10.1152/ajpcell.00527.2008, 2724095, 19386787.
27. Moraes TJ, Plumb J, Martin R, Vachon E, Cherepanov V, Koh A, Loeve C, Jongstra-Bilen J, Zurawska JH, Kus JV, et al. Abnormalities in the pulmonary innate immune system in cystic fibrosis. Am J Respir Cell Mol Biol 2006, 34:364-374. 10.1165/rcmb.2005-0146OC, 2644201, 16293782.
28. Matsui H, Wagner VE, Hill DB, Schwab UE, Rogers TD, Button B, Taylor RM, Superfine R, Rubinstein M, Iglewski BH, et al. A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci USA 2006, 103:18131-18136. 10.1073/pnas.0606428103, 1838718, 17116883.
29. Cystic Fibrosis Foundation: Patient Registry 2008 Annual Report 2008, Bethesda, MD.